


Looking for 3 postdoctoral research fellows

The GLYNTERA lab

Sun, Sea and Science

Location: The **Glycosylation, Cellular Interfaces and Therapies** group is opening at the Center for Cancer Research in Marseille, France: <https://www.crcm-marseille.fr/en>. The CRCM is on the Institut Paoli Calmettes campus: <https://www.institutpaolicalmettes.fr/>.



Time: Recruiting from November 2021 onwards

Focus: How tumor cells interact with other cells is critical for tumor growth and thus cancer therapies. The lab concentrates on how the glycosylation of proteins regulates the interfaces between tumor cells and extracellular matrices and other cells, stromal, epithelial and immune. The group has discovered a new signaling and glycosylation pathway, called GALA, controlling surface proteins and activated in most solid tumors ^{1,2}. This pathway led us to identify a new surface target and develop antibodies with therapeutic potential ³.

Approach: In addition to the usual techniques of molecular and cell biology, we will develop organoids, high-throughput 3D imaging and mouse models of liver cancer.

People: Frederic Bard is moving to the CRCM after leading a lab in IMCB in Singapore for the last 15 years. Together with Malgo, a research engineer, we are building up the new group.

Support: The lab is supported by a Leader in Oncology grant from ARC, an excellence initiative grant (AMIDEX) from AMU and the CRCM.

Who you are: Enthusiastic about science, able to work independently, with a good track record and, ideally, a good mastery of written english. You have a background in cell biology, organoids, signaling in cancer, immunology or mouse models.

Application: Send your CV and motivation letter to fredbard@gmail.com

1. Bard F, Chia J. Cracking the Glycome Encoder: Signaling, Trafficking, and Glycosylation. Trends Cell Biol. 2016 May;26(5):379–388. PMID: 26832820
2. Nguyen AT, Chia J, Ros M, Hui KM, Saltel F, Bard F. Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and Metastasis. Cancer Cell. 2017 Nov 13;32(5):639–653.e6. PMID: 29136507
3. Ros M, Nguyen AT, Chia J, Le Tran S, Le Guezennec X, McDowall R, Vakhrushev S, Clausen H, Humphries MJ, Saltel F, Bard FA. ER-resident oxidoreductases are glycosylated and trafficked to the cell surface to promote matrix degradation by tumour cells. Nat Cell Biol. 2020 Nov;22(11):1371–1381. PMID: 33077910

